2022年8月27日 · We designed the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial to test the hypothesis that the SGLT2...

2023年8月1日 · These findings support the use of SGLT-2 inhibitors in HFpEF and HFmrEF, potentially influencing clinical practice and future guidelines. The DELIVER trial investigated the efficacy and safety of dapagliflozin in patients with heart failure and preserved or mildly reduced ejection fraction.

The DELIVER trial confirmed the extended benefits of SGLT-2 inhibitors in terms of reduced heart failure hospitalization and cardiovascular death in patients with HFmrEF and HFpEF, regardless of the presence of type 2 diabetes mellitus.

2022年8月27日 · In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, the sodium glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin was shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF with mildly reduced or preserved ejection ...

8月27日，在2022年欧洲心脏病学会（ESC）年会上公布的DELIVER研究，以及同时发表的该研究多项亚研究和相关Meta分析证实，SGLT2i对各类心衰患者，均可显著降低心血管死亡和心衰住院风险。

2022年8月28日 · 这是钠-葡萄糖共转运体-2抑制剂 (SGLT2i)在射血分数保存的心衰（HFpEF）患者中的临床试验（EMPOROR-preserved，恩格列净）取得成功之后，又一次的重大探索。 心衰学者一直满怀期待又惴惴不安地等待着。 研究结果如为阴性，将产生颠覆性影响，质疑SGLT2i用于HFpEF的价值，危及心衰现代治疗的架构。 研究的阳性结果，使SGLT2i再次绽放光彩，奠定了此类药治疗包括HFpEF在内的各种心衰的基石地位，一骑绝尘，成为津津乐道的新议题，但也留 …

Originally intended to treat diabetes, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) were shown to reduce HF events among adults with LVEF ≤40% (i.e., HFrEF) in the 2019 DAPA-HF and 2020 EMPEROR-Reduced trials.

2022年8月29日 · Deliver试验旨在研究达格列净在HFmrEF和HFpEF患者中的有效性及安全性，为全球多中心、双盲、安慰剂对照临床研究，研究共纳入了20个国家353个地区累计6263例有症状的心衰患者，纳入患者人群平均年龄72岁、LVEF＞40%（平均54%），女性患者约44%。

2022年8月27日 · BARCELONA, Spain—(UPDATED) Full results of the DELIVER trial, flanked by several other analyses, demonstrate that the sodium-glucose cotransporter 2 (SGLT2) inhibitors provide benefits to patients with heart failure (HF) irrespective of ejection fraction.

2022年9月3日 · Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction.